Aligarh: Dr Hifzur R. Siddique, Department of Zoology, Aligarh Muslim University, who has been doing research on cancer for the last several years, has been included as a part of the world expert consensus on the strategy to diagnose and treat NUT carcinoma.
Dr Siddique is the only Indian to become the part of 101 scientists from different countries, including USA, UK, China, Italy, Sweden, Portugal, Spain, Greece, Austria, Singapore, Egypt, and Russia to work on the NUT Carcinoma, which was first reported in 1991. It is a rare and highly aggressive malignancy with a dismal prognosis and a median survival of 6-9 months only.
Dr Siddique pointed out that ‘Nuclear protein of the testis’ (NUT) carcinoma is a rare and highly aggressive malignancy characterised by the rearrangement of the NUT midline carcinoma family member 1 (NUTM1) gene and less than 200 cases are diagnosed in the US each year.
He said standardised strategies for its diagnosis and treatment remained unavailable, underscoring the need for an expert consensus. To address this gap, the scientific team prepared this consensus for the diagnosis and treatment of NUT carcinoma. The team comprised medical oncologists, radiation oncologists, surgical oncologists, pathologists, nurses, molecular biologists, statisticians, and bioinformatics specialists.
The AMU researcher mentioned that the team developed the expert consensus on diagnosing and treating NUT carcinoma using a multidisciplinary approach and the guideline provides eight recommendations, addressing epidemiological characteristics, clinical and imaging manifestations, pathological findings, IHC features, molecular mechanisms and subtypes, prognosis, diagnosis, and treatment strategies for this cancer. Furthermore, an international platform has been established to disseminate NUT carcinoma knowledge and patient recruitment, providing patients and healthcare providers’ access to NUT carcinoma-related information and updates on clinical trial recruitment.
